Vulvar disease

This trial tests whether combining an immune-boosting cream (imiquimod) with a low dose of an immunotherapy drug (nivolumab) can shrink vulvar squamous cell carcinoma tumors before surgery. About 50 women with resectable, early-to-moderate stage vulvar cancer will receive the dru…

This phase 2 trial tests a drug called tisotumab vedotin in people with advanced squamous cell carcinoma of the vulva that has returned or spread. The drug is an antibody-drug conjugate designed to seek out and destroy cancer cells. The study aims to see how many participants' tu…

This early-stage trial tests a topical ointment called ACU-D1 for HPV-related vulvar and perianal lesions in people with HIV. Nine participants will apply the cream twice daily for 4 weeks. The main goal is to find the safest dose and see if the treatment can boost immune markers…

This study tests whether regular ultrasound checks of the groin can safely replace the standard surgery to remove lymph nodes in women with early-stage vulvar cancer. The goal is to reduce side effects and improve recovery while still keeping the cancer under control. About 640 w…

This study compares three treatments for vulvar lichen sclerosus, a chronic skin condition causing itching and pain. 45 women aged 30-80 will receive either a steroid cream, an immune-modulating cream, or platelet-rich plasma (PRP) injections. The goal is to see which approach be…

This study will test a new diagnostic device called the Nanopath assay, which aims to quickly detect bacteria or yeast causing vaginitis. Up to 1000 women with symptoms like itching or discharge will provide vaginal swab samples, either collected by a clinician or themselves. The…

This pilot study will test whether a fluorescent dye called indocyanine green (ICG), used with a special handheld camera, can find sentinel lymph nodes as well as the standard blue dye in early-stage vulvar cancer. Ten patients will receive both dyes during surgery, and doctors w…

This study tests whether the HPV vaccine can prevent the return of high-grade squamous intraepithelial lesions (HSIL) in people who have already been treated for them. About 984 adults aged 18–55 with HPV-related HSIL of the cervix, vulva, vagina, penis, or anus will receive eith…

This study tests whether an oral collagen supplement (Collagendep) can reduce vulvar dryness in 40 women with genital lichen sclerosus who are also receiving fat grafting. Participants take the supplement daily for 4 months. The main goal is to see if dryness improves, with secon…

This study tests whether a cream containing both testosterone and estrogen works better than estrogen alone to reduce pain during sex for women with vulvodynia. About 44 adult women with moderate to severe pain will use one of the two creams daily. The goal is to find a more effe…

This study tests a behavioral program to help women who have had pelvic radiation use vaginal dilators more regularly. Dilators can prevent or treat vaginal narrowing that makes exams or sex painful. 88 women will be randomly assigned to either the program (with coping strategies…

This study follows 42 women with HPV-positive pelvic cancer (cervix, vagina, vulva, or anus) to understand how radiotherapy, with or without surgery, affects their sexual quality of life. Participants complete questionnaires about sexual function and emotional distress over time.…

This study tests whether point-of-care STI tests, which give results in about 10 minutes, can speed up treatment for pregnant women compared to standard lab tests. About 756 pregnant women at Grady Memorial Hospital will either get the rapid tests or standard testing. The goal is…

This study looks at how well patients do after surgery that removes both advanced gynecologic cancers and the major blood vessels they have grown into. Researchers will track 130 participants for up to 5 years to see survival rates and how long it takes for the cancer to return. …

This study looks back at the medical records of 200 people treated for gynecological cancers (like ovarian, cervical, or uterine cancer) at Assiut University Hospital between 2022 and 2025. The goal is to measure how long patients survive after diagnosis and compare those numbers…